IP Library Granted Patent US 6,942,980
Granted Patent B1
US 6,942,980 · App. 09/685,828 · Granted Sep 13, 2005

Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,942,980
App. No.
09/685,828
Granted
Sep 13, 2005
Kind
B1
Abstract

Methods of characterizing and identifying negative hormones of nuclear receptors. Also disclosed are methods of making modulators of retinoid nuclear receptor transactivation activity, assays for agonists, antagonists, and negative hormones of the RAR receptor, and specific retinoid modulators of retinoid nuclear receptors.

Claims (7)

1. A method for determining whether a compound is an inverse agonist of a retinoid receptor comprising the steps:

a) contacting a polypeptide comprising a ligand binding region and a ligand dependent transactivation region of said retinoid receptor with a test compound in the presence of a reporter gene, wherein the expression of said reporter gene is sensitive to stimulation by said retionoid receptor in the presence of an agonist of said retinoid receptor, and

b) determining the ability said polypeptide to stimulate expression of said reporter gene in the presence of said test compound as compared to the ability of said polypeptide to stimulate expression of said reporter gene in the basal state, said basal state occurring in the absence of a ligand of said retinoid receptor,

wherein repression of the ability of said polypeptide to stimulate expression of said reporter gene in the presence of the test compound relative to the basal state according to step b indicates that the test compound is an inverse agonist.

2. The method of claim 1 wherein said reporter gene is integrated into the chromosome of a host cell.

3. The method of claim 1 wherein said reporter gene is comprised in a plasmid expressed by a host cell.

4. The method of claim 1 wherein said reporter gene encodes a protein having an activity selected from the group consisting of a luciferase activity and a β-galactosidase activity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2003
From: ALLERGAN SALES, LLC (FORMERLY IN THE NAME OF VISION PHARMACEUTICALS L.P. OR ALLERGAN - WITH WACO OR DUPONT ADDRESS)
To: ALLERGAN, INC.
Reel/Frame 013965/0566 →